Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?
Clinical & Translational Immunology · 2023-01 · 12 (10)
DOI: 10.1002/cti2.1469 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical & Translational Immunology, online erschienen am 29.09.2023. Verfasst von Alessia Furgiuele und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research in Medical Pharmacology University of Insubria Varese Italy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Parkinson's disease (PD) is a neurodegenerative disease affecting 7–10 million people worldwide. Currently, there is no treatment available to prevent or delay PD progression, partially due to the limited understanding of the pathological events which lead to the death of dopaminergic neurons in the substantia nigra in the brain, which is known to be the cause of PD symptoms. The current available treatments aim at compensating dopamine (DA) deficiency in the brain using its precursor levodopa, dopaminergic agonists and some indirect dopaminergic agents. The immune system is emerging as a critical player in PD. Therefore, immune‐based approaches have recently been proposed to be used as potential antiparkinsonian agents. It has been well‐known that dopaminergic pathways play a significant role in regulating immune responses in the brain. Although dopaminergic agents are the primary antiparkinsonian treatments, their immune regulatory effect has yet to be fully understood. The present review summarises the current available evidence of the immune regulatory effects of DA and its mimics and discusses dopaminergic agents as antiparkinsonian drugs. Based on the current understanding of their involvement in the regulation of neuroinflammation in PD, we propose that targeting immune pathways involved in PD pathology could offer a better treatment outcome for PD patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Research in Medical Pharmacology University of Insubria Varese Italy.
- Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics University of Coimbra Coimbra Portugal.
- Faculty of Medicine, Institute for Clinical and Biomedical Research (iCBR) University of Coimbra Coimbra Portugal.
- Center for Innovative Biomedicine and Biotechnology (CIBB) University of Coimbra Coimbra Portugal.
- Clinical Academic Center of Coimbra (CACC) Coimbra Portugal.
ORCID-Profile: Alessia Furgiuele, Marco Cosentino
Zitieren
APA
Furgiuele, A., Pereira, F. C., Martini, S., Marino, F., & Cosentino, M. (2023). Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?. Clinical & Translational Immunology, 12(10). https://doi.org/10.1002/cti2.1469
Vancouver
Furgiuele A, Pereira FC, Martini S, Marino F, Cosentino M. Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?. Clinical & Translational Immunology. 2023;12(10). doi:10.1002/cti2.1469
BibTeX
@article{Furgiuele2023,
author = {Furgiuele, Alessia and Pereira, Frederico C and Martini, Stefano and Marino, Franca and Cosentino, Marco},
title = {Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?},
journal = {Clinical & Translational Immunology},
year = {2023},
volume = {12},
number = {10},
doi = {10.1002/cti2.1469}
}
EUVIMED